Peili Vision

Company Description

Peili Vision is at the forefront of revolutionizing ADHD diagnostics and neurological care with our innovative digital solutions. Our flagship product, EFSim, offers a faster, more accessible, and 92% accurate diagnosis of ADHD symptoms through immersive web-based simulations. We’ve already seen remarkable results, including a 43% reduction in waiting times for ADHD assessments, making a significant impact on patient care and healthcare efficiency. With completed clinical trials, Peili Vision is fully UKCA-certified and now free to operate in the UK market. We are preparing for our EU launch in January 2025 under the CE MDR II certification, ensuring compliance with the highest medical device standards. Our evidence-backed solutions integrate diagnostics, rehabilitation, and medication evaluation directly into patients’ homes, providing seamless remote care. Supported by €2.5M in EIC grant funding and a potential €2M equity investment, we are ready to scale globally, starting with the UK and EU. While our current focus is on ADHD, we are expanding into broader neurological challenges, all while delivering a measurable impact on healthcare accessibility and outcomes. Join us in transforming remote healthcare and unlocking new possibilities for patients, clinicians, and caregivers worldwide. Peili Vision is ready to lead the way in making high-quality, efficient, and research-driven healthcare solutions accessible to all.